Yamanouchi to develop ImaRx agent

Article

Japanese drug firm Yamanouchi Pharmaceutical has begun clinical development in Japan of YM454, the company's version of an ultrasound contrast agent licensed from ImaRx Pharmaceutical of Tucson. Yamanouchi has Asian marketing rights for the agent, which

Japanese drug firm Yamanouchi Pharmaceutical has begun clinical development in Japan of YM454, the company's version of an ultrasound contrast agent licensed from ImaRx Pharmaceutical of Tucson. Yamanouchi has Asian marketing rights for the agent, which ImaRx is co-developing in the U.S. with Du Pont Pharmaceutical under the name DMP115.

Related Videos
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2023 MJH Life Sciences

All rights reserved.